Linked Life Data

18037292

Source:http://linkedlifedata.com/resource/pubmed/id/18037292

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-6-2
pubmed:abstractText
Many active cytotoxic drugs, given according to a number of different regimens are approved for the treatment of metastatic breast cancer patients. However, these therapies have not changed the outcome of patients affected by this malignancy. As a consequence, the balance between chemotherapy-induced side effects and relief of cancer-related symptoms must be carefully considered in this setting. Gemcitabine is an antimetabolite that is incorporated as a triphosphate into DNA. As a single agent, it yields responses rates ranging from 14% to 37% in chemotherapy-naïve patients and from 12% to 30% in patients previously treated with anthracyclines and/or taxanes. In combination with paclitaxel, it produces a significantly higher response rate (41.4% vs. 26.2%), longer time to progression (6.1 vs. 4 months) and significantly higher overall survival (18.6 vs. 15.8 months) than paclitaxel alone. In addition, a phase III study revealed that gemcitabine plus docetaxel is as effective as capecitabine plus docetaxel, but causes significantly less non-haematologic toxicity. Lastly, in another phase III trial, progression free survival was significantly longer with the combination of gemcitabine plus vinorelbine than with vinorelbine alone (6 vs. 4 months), but without a significant difference in overall survival; the incidence of haematologic toxicity was higher in the group treated with combined therapy. Novel gemcitabine combinations are being investigated in phase II studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0960-9776
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
220-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18037292-Adult, pubmed-meshheading:18037292-Antibodies, Monoclonal, pubmed-meshheading:18037292-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18037292-Antimetabolites, Antineoplastic, pubmed-meshheading:18037292-Antineoplastic Agents, Phytogenic, pubmed-meshheading:18037292-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18037292-Breast Neoplasms, pubmed-meshheading:18037292-Clinical Trials, Phase II as Topic, pubmed-meshheading:18037292-Clinical Trials, Phase III as Topic, pubmed-meshheading:18037292-Deoxycytidine, pubmed-meshheading:18037292-Disease Progression, pubmed-meshheading:18037292-Female, pubmed-meshheading:18037292-Humans, pubmed-meshheading:18037292-Taxoids, pubmed-meshheading:18037292-Treatment Outcome, pubmed-meshheading:18037292-Vinblastine
pubmed:year
2008
pubmed:articleTitle
Role of gemcitabine in metastatic breast cancer patients: a short review.
pubmed:affiliation
Operative Unit of Medical Oncology, Moscati General Hospital, Via per Martina Franca, 74100 Taranto, Italy. nicolasilvestris@virgilio.it
pubmed:publicationType
Journal Article, Review